Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This article discusses using high performance liquid chromatography to optimize mobile phase composition for separating synthesis products of Finasteride, without reporting new clinical results.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

This study found that a new compounded topical solution for alopecia was clinically tolerable and did not cause irritation, while also showing potential to enhance hair growth through fibroblast proliferation and gene expression.

This study analyzed real-world clinical data to describe the characteristics and medication patterns of Compound Jinqiancao Granules used to treat prostatitis, highlighting prevalent age groups, common co-medications, and traditional Chinese medicine principles, while noting the limitations in drawing causal inferences due to study design.

In this study, compound glycyrrhizin promoted hair regrowth in a testosterone-induced alopecia mouse model and increased human hair dermal papilla cell proliferation, likely through activating the Wnt/β-catenin pathway.

In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.

This review outlines recent advancements in droplet-based microfluidics used with food-grade materials to create delivery systems, emphasizing the design and function of systems like emulsions and microcapsules while discussing challenges related to scaling these processes from lab to industry.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This review highlights various plant-based and herbal treatments that reportedly help prevent hair loss and encourage hair growth. It also explores the molecular mechanisms, identified plant compounds, recent technologies such as nanoarchitectonics, and patents related to hair growth promotion.

This study concluded that mixtures of weak endocrine disruptors, such as parabens and azole fungicides, can produce combination effects that should be considered in regulatory risk assessments to avoid underestimating potential risks.

This study developed a validated method to detect prohibited drugs in dietary supplements, finding minoxidil, triaminodil, and finasteride in some samples.

This chapter reviews various types of aromatic compounds and provides references, but reports no new experimental results.

This study suggests that compounds from Sansevieria trifasciata Prain may have promising potential as effective 5α-reductase inhibitors for alopecia treatment, outperforming finasteride in binding affinity tests.

This study developed a rapid method using advanced chromatography and mass spectrometry to detect hair-growth enhancing compounds, discovering synthetic drugs in about 21% of tested supplements.

This study developed and validated a method using UPLC-PDA and LC-Q-TOF/MS to identify and measure prohibited substances in dietary supplements, showing reliable detection of compounds like minoxidil and finasteride.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This study found that solid-state NMR combined with X-ray techniques provided critical insights into the structure and solvation of finasteride polymorphs, identifying gaps in existing patent characterizations.

This research outlines a chemical synthesis process for Finasteride, detailing the conversion of pregnadienolone acetate through various chemical reactions and modifications.

This study found that phytosterols extracted from moringa seed oil may act as potential anti-alopecia agents by inhibiting the 5α-reductase enzyme, with ergostadienol showing particularly high affinity and stability in in silico simulations.

This study investigated the potential of nutmeg-derived phytochemicals as anti-alopecia agents using molecular docking and simulations, finding that geranylgeraniol exhibited significant binding stability and potential efficacy against androgenetic alopecia comparable to finasteride and superior to minoxidil.

This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.